Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US

With recent increases in buprenorphine treatment for opioid use disorder (OUD), is buprenorphine misuse increasing in the US?

Original research | 2021

Hesitancy of prescribers , About prescribers, About PWUD, Substitution/OAT

Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program

This study describes the transition of The Spot’s buprenorphine service to telemedicine during the COVID-19 pandemic and one year treatment retention.

Original research | 2021

About prescribers, Outcomes, Substitution/OAT, Digital health

Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Infographic | 2021

Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender

Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Update data from the 2020 preliminary report on opioid-related deaths before and during the pandemic

Report | 2021

Overdose, Mortality, Evidence base, Advocacy, Housing, Illegal drugs, Workplace, Rural/remote, Stimulants, Sex/Gender

Effectiveness of peer recovery support services on stages of the opioid use disorder treatment cascade: a systematic review

Peer recovery support services (PRSS) have been increasingly incorporated during the recovery process for opioid use disorder (OUD), yet little is known about the effects of PRSS on clinical outcomes

Lit review | 2021

Wrap-around services, About PWUD, Social services, Peer/PWLLE program involvement

Harm Reduction in the United States at a Moment of Change; Moving Innovation from Grassroots to Mainstream?

Commentary | 2009

Policy/Regulatory

Heroin Assisted Treatment: The state of play

This briefing paper explores the question of Heroin Assisted Treatment (HAT), examines the growing body of evidence emerging from its clinical use in addiction therapies, and makes recommendations for

Report | 2010

Evidence base, Policy/Regulatory, Advocacy

Injectable opioid agonist treatment: An evolutionary concept analysis

Concept analysis for moving forward with iOAT

Commentary | 2021

Advocacy, Crime, Illegal drugs, Peer/PWLLE program involvement, Mental health

Letter from the Minister of Health regarding treatment and safer supply

Letter | 2020

Mortality, Policy/Regulatory, Safer supply, Advocacy, Illegal drugs

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report

Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, and opioid dependence from PST use can develop.

Original research | 2021

Withdrawal, Clinical guidance, Hesitancy of prescribers , About prescribers, Outcomes, Chronic pain, Substitution/OAT, Stigma

Peer engagement in harm reduction strategies and services: a critical case study and evaluation framework from British Columbia, Canada

This paper aims to describe and evaluate peer engagement in British Columbia from 2010–2014.

Original research | 2016

Evidence base, About PWUD, Peer/PWLLE program involvement

Peer Engagement Principles and Best Practices: A Guide for BC Health Authorities and Other Providers, version 2

Peers can provide insights into the realities of substance use and their local risk environments, and the applicability of programs and policies.

Guidelines | 2018

Equity, Peer/PWLLE program involvement

Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Infographic | 2020

Overdose, Mortality, Evidence base, Safer supply, Advocacy, Social services, Poverty, Housing, Illegal drugs, Sex/Gender

Preliminary Patterns in Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic

Examination of suspected opioid-related deaths in Ontario before and during the pandemic

Report | 2020

Overdose, Mortality, Evidence base, Safer supply, Advocacy, Social services, Poverty, Housing, Illegal drugs, Sex/Gender

Regulation of illegal drugs: an exploration of public health tools

This commentary explores the concept of a regulated market for currently illegal drugs

Commentary | 2004

Evidence base, Policy/Regulatory, Decriminalization/legalization, Advocacy

Safer Opioid Supply Programs (SOS): A Harm Reduction Informed Guiding Document for Primary Care Teams

Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.

Guidelines | 2020

Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion

STOPS: A Journey of Grassroots Overdose Prevention from Northeastern Ontario

Slide deck | 2021

Overdose, Mortality, Harm reduction, Small/medium cities, SCS/OPS

Substance Replacement Therapy in the Context of the COVID-19 Pandemic in Québec: Clinical Guidance for Prescribers

Quebec safe supply clinical guidance for prescribers

Guidelines | 2020

Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs

Substance Use (SU) among Women in the Context of the Corollary Pandemics of COVID-19 and Intimate Partner Violence (IPV)

Examines the disparate literatures on 1) disasters/pandemics and intimate partner violence, and 2) on the relationship between intimate partner violence and substance use

Lit review | 2020

Sex/Gender

The drug toxicity and overdose crisis in Canada: a snapshot of what the current data tell us

This article provides a snapshot of data released by Health Canada on opioid- and stimulant-related harms and data from two provinces detailing a concerning trend in the nature of drug toxicity dea

Newsletter | 2021

Overdose, Mortality, Harm reduction, Policy/Regulatory, Safer supply, Decriminalization/legalization, Illegal drugs, Stimulants, SCS/OPS